Physician profile
Daniel M Silverstein
NPI 1932105038
$3,177.39
in general payments reported to CMS, 2019-2025
28 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $52.61 · 2021: $60.72 · 2022: $218 · 2023: $611 · 2024: $736 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.13 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $422.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $281.71 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $272.80 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $171.62 | 2019-2025 | |
| Astellas Pharma US INC | $166.39 | 2019-2025 | Veozah |
| Gilead Sciences, INC. | $139.74 | 2019-2025 | |
| Amgen INC. | $92.85 | 2019-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.90 | 2019 | |
| Glaxosmithkline, LLC. | $77.92 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Stryker Corporation | $69.27 | 2023 | Xpress Ent Dilation System |
| Abbott Laboratories | $65.21 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $61.56 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $58.05 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $51.41 | 2022 | |
| Viiv Healthcare Company | $45.42 | 2025 | Apretude |
| Inspire Medical Systems, INC. | $38.03 | 2023-2025 | Inspire |
| Dynavax Technologies Corporation | $37.82 | 2022-2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $30.19 | 2019 | |
| Bausch Health US, LLC | $21.40 | 2025 | Wellbutrin |
| Janssen Biotech, INC. | $19.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.39 | 2021 | |
| Hologic Sales and Service, LLC | $15.24 | 2025 | Thinprep 2000 Processor, Aptima |
| Ultragenyx Pharmaceutical INC. | $14.17 | 2023 | Crysvita |
| Merck Sharp & Dohme LLC | $12.66 | 2019 | |
| Allergan, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.